OncoMatch/Clinical Trials/NCT04808323
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
Is NCT04808323 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for rectal adenocarcinoma.
Treatment: Capecitabine · Initial Dose of Radiation before Dose Escalation · Cohort A: Dose Escalation Radiation · Cohort B: Dose Escalation Radiation · Cohort C: Dose Escalation Radiation · FOLFOX — This study is a prospective, open-label, phase I design.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage I, II, III
Excluded: Stage IV
Determined on staging evaluation to be clinical stage I, II or III.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
ANC ≥ 1,000 cells/mm3; platelets ≥50,000 cells/mm3; hemoglobin ≥ 8.0 g/dl (transfusion/intervention allowed).
Kidney function
Not on hemodialysis. If age over 60, history of hypertension, diabetes or liver transplant, and GFR at enrollment is < 30 [excluded].
Liver function
ALT or AST < 4 x upper limit of normal; total bilirubin < 2 x upper normal mg/dL; alkaline phosphatase < 4 x upper limit of normal.
Laboratory values (CBC, Chem24) 45 days prior to treatment as follows: Carcinoembryonic antigen (CEA) (any value). Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3. Platelets ≥50,000 cells/mm3. Hemoglobin ≥ 8.0 g/dl. (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 4 x upper limit of normal. Total bilirubin < 2 x upper normal mg/dL. Alkaline phosphatase < 4 x upper limit of normal. Not on hemodialysis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04808323 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages